Firehawk® Rapamycin Target Eluting Coronary Stent System

Written By Richard Pablo

CLINICAL EVIDENCE

Firehawk® as the first and only Target Eluting Stent (TES), features over 600 groves on the stent strut surface, and a target release technology that allows for 1/3 of the dosage versus conventional stents.

The result is a unique solution that combines the strength of both drug eluting stents and bare metal stents.

With the continuous increase in the body of clinical evidence to demonstrate its 'golden standard' in safety and efficacy, Firehawk® is establishing its status as an elite workhorse drug-eluting stent for clinics across the globe.

TARGET All Comers Trial1

  • 1,656 Patients from 20 sites in Europe

  • 1:1 RCT Real World open-label, non-inferiority trial

  • Primary endpoint: TLF @12 months

  • Confirms that the Firehawk®, a low dose sirolimus eluting biodegradable polymer DES, is safe
    and effective across a broad spectrum of patient and lesion complexity

PROB/DEFINITE STENT THROMBOSIS AT 1 YEAR

  • 1-year Stent thrombosis rate result shows non-inferiority than Durable-Polymer DES

  • Shows proven safety in all comers population

Richard Pablo
Next

FOXTROT® PTCA Balloon Catheter